1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Humira Shows Benefit In New Arthritis Indications Based On Novel Criteria

 
• By Jessica Merrill

Abbott’s anti-TNF demonstrated an improvement in two subsets of spondyloarthritis patients using new criteria developed by the SpondyloArthritis International Society to identify and test patients.

Abbott Laboratories Inc.’s blockbuster arthritis drug Humira (adalimumab) demonstrated an improvement in two new subsets of spondyloarthritis patients for which the drug is not currently indicated in Phase III studies presented at the European League Against Rheumatism (EULAR) Congress in Berlin June 6.

Data from two studies showed that Humira provided a benefit to patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis or ankylosing spondylitis and in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

More from R&D